Literature DB >> 23788580

Trial designs for personalizing cancer care: a systematic review and classification.

Parvin Tajik1, Aleiko H Zwinderman, Ben W Mol, Patrick M Bossuyt.   

Abstract

There is an increasing interest in the evaluation of prognostic and predictive biomarkers for personalizing cancer care. The literature on the trial designs for evaluation of these markers is diverse and there is no consensus in the classification or nomenclature. We set this study to review the literature systematically, to identify the proposed trial designs, and to develop a classification scheme. We searched MEDLINE, EMBASE, Cochrane Methodology Register, and MathSciNet up to January 2013 for articles describing these trial designs. In each eligible article, we identified the trial designs presented and extracted the term used for labeling the design, components of patient flow (marker status of eligible participants, intervention, and comparator), study questions, and analysis plan. Our search strategy resulted in 88 eligible articles, wherein 315 labels had been used by authors in presenting trial designs; 134 of these were unique. By analyzing patient flow components, we could classify the 134 unique design labels into four basic patient flow categories, which we labeled with the most frequently used term: single-arm, enrichment, randomize-all, and biomarker-strategy designs. A fifth category consists of combinations of the other four patient flow categories. Our review showed that a considerable number of labels has been proposed for trial designs evaluating prognostic and predictive biomarkers which, based on patient flow elements, can be classified into five basic categories. The classification system proposed here could help clinicians and researchers in designing and interpreting trials evaluating predictive biomarkers, and could reduce confusion in labeling and reporting. ©2013 AACR.

Entities:  

Mesh:

Year:  2013        PMID: 23788580     DOI: 10.1158/1078-0432.CCR-12-3722

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Authors:  Ariel Lopez-Chavez; Anish Thomas; Arun Rajan; Mark Raffeld; Betsy Morrow; Ronan Kelly; Corey Allan Carter; Udayan Guha; Keith Killian; Christopher C Lau; Zied Abdullaev; Liqiang Xi; Svetlana Pack; Paul S Meltzer; Christopher L Corless; Alan Sandler; Carol Beadling; Andrea Warrick; David J Liewehr; Seth M Steinberg; Arlene Berman; Austin Doyle; Eva Szabo; Yisong Wang; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

Review 2.  Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Authors:  Brian M Alexander; Evanthia Galanis; W K Alfred Yung; Karla V Ballman; James M Boyett; Timothy F Cloughesy; John F Degroot; Jason T Huse; Bhupinder Mann; Warren Mason; Ingo K Mellinghoff; Tom Mikkelsen; Paul S Mischel; Brian P O'Neill; Michael D Prados; Jann N Sarkaria; Abdul Tawab-Amiri; Lorenzo Trippa; Xiaobu Ye; Keith L Ligon; Donald A Berry; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2014-08-26       Impact factor: 12.300

3.  Platform trials arrive on time for glioblastoma.

Authors:  Brian M Alexander; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

4.  Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer.

Authors:  Holly Janes; Marshall D Brown; Michael R Crager; Dave P Miller; William E Barlow
Journal:  Contemp Clin Trials       Date:  2017-08-14       Impact factor: 2.226

5.  On Enrichment Strategies for Biomarker Stratified Clinical Trials.

Authors:  Xiaofei Wang; Jingzhu Zhou; Ting Wang; Stephen L George
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

6.  Designing a study to evaluate the benefit of a biomarker for selecting patient treatment.

Authors:  Holly Janes; Marshall D Brown; Margaret S Pepe
Journal:  Stat Med       Date:  2015-06-25       Impact factor: 2.373

Review 7.  Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Ruwanthi Kolamunnage-Dona; Andrea L Jorgensen
Journal:  J Pers Med       Date:  2017-01-25

Review 8.  Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers.

Authors:  Ravi Dhingra; Ramachandran S Vasan
Journal:  Trends Cardiovasc Med       Date:  2016-07-28       Impact factor: 6.677

Review 9.  Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test.

Authors:  Rodrigo Dienstmann; Jordi Rodon; Josep Tabernero
Journal:  Mol Oncol       Date:  2014-07-15       Impact factor: 6.603

10.  Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.

Authors:  Alexandre Vivot; Isabelle Boutron; Philippe Ravaud; Raphaël Porcher
Journal:  Genet Med       Date:  2014-12-18       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.